<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DISEASE CHARACTERISTICS: Spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>), also known as <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>), is characterized by <z:hpo ids='HP_0002073'>progressive cerebellar ataxia</z:hpo> and variable findings including a dystonic-rigid syndrome, a <z:e sem="disease" ids="C0242422" disease_type="Disease or Syndrome" abbrv="">parkinsonian syndrome</z:e>, or a combined syndrome of <z:hpo ids='HP_0001332'>dystonia</z:hpo> and <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Neurologic findings tend to evolve as the disease progresses </plain></SENT>
<SENT sid="2" pm="."><plain>DIAGNOSIS/TESTING: The diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> rests on the use of molecular genetic testing to detect an abnormal CAG trinucleotide repeat expansion in ATXN3 </plain></SENT>
<SENT sid="3" pm="."><plain>Affected individuals have alleles with 52 to 86 CAG trinucleotide repeats </plain></SENT>
<SENT sid="4" pm="."><plain>Such testing detects 100% of affected individuals and is available in clinical laboratories </plain></SENT>
<SENT sid="5" pm="."><plain>MANAGEMENT: Treatment of manifestations: Management is supportive as no medication slows the course of disease; <z:e sem="disease" ids="C0035258" disease_type="Disease or Syndrome" abbrv="">restless legs syndrome</z:e> and <z:hpo ids='HP_0002071'>extrapyramidal syndromes</z:hpo> resembling <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> may respond to <z:chebi fb="0" ids="15765">levodopa</z:chebi> or <z:chebi fb="0" ids="51065">dopamine agonists</z:chebi>; <z:hpo ids='HP_0001257'>spasticity</z:hpo>, <z:hpo ids='HP_0002307'>drooling</z:hpo>, and <z:e sem="disease" ids="C0851578,C0700201" disease_type="Disease or Syndrome" abbrv="">sleep problems</z:e> respond variably to lioresal, <z:chebi fb="28" ids="16684">atropine</z:chebi>-like drugs, and hypnotic agents; botulinum toxin has been used for <z:hpo ids='HP_0001332'>dystonia</z:hpo> and <z:hpo ids='HP_0001257'>spasticity</z:hpo>; daytime <z:mp ids='MP_0002899'>fatigue</z:mp> may respond to psychostimulants such as modafinil; accompanying <z:hpo ids='HP_0000716'>depression</z:hpo> should be treated </plain></SENT>
<SENT sid="6" pm="."><plain>Affected individuals should remain active; canes and walkers help prevent falling; motorized scooters can help maintain independence; <z:e sem="disease" ids="C0009460,C0699719,C0037831" disease_type="Mental or Behavioral Dysfunction;Therapeutic or Preventive Procedure;Finding" abbrv="">speech therapy</z:e> and communication devices may benefit those with <z:hpo ids='HP_0001260'>dysarthria</z:hpo> and dietary modification those with <z:hpo ids='HP_0002015'>dysphagia</z:hpo>; weighted eating utensils and dressing hooks help to maintain independence </plain></SENT>
<SENT sid="7" pm="."><plain>Prevention of secondary complications: modification of the home for safety; vitamin supplements if caloric intake is reduced; weight control to facilitate ambulation and mobility; caution with general anesthesia </plain></SENT>
<SENT sid="8" pm="."><plain>Surveillance: annual or biannual assessment of speech, swallowing, and gait function </plain></SENT>
<SENT sid="9" pm="."><plain>GENETIC COUNSELING: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> is inherited in an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> manner </plain></SENT>
<SENT sid="10" pm="."><plain>Offspring of affected individuals have a 50% chance of inheriting the mutation </plain></SENT>
<SENT sid="11" pm="."><plain>Prenatal testing is possible for pregnancies at increased risk if the diagnosis has been confirmed in an affected family member </plain></SENT>
</text></document>